Illumina Aktie
WKN: 927079 / ISIN: US4523271090
|
05.01.2024 16:28:34
|
Illumina Collaborates With Janssen To Develop MRD Cancer Test
(RTTNews) - Illumina, Inc. (ILMN), a DNA sequencing and array-based technologies firm, Friday announced that it has signed an agreement with Janssen Research and Development, LLC to develop its novel molecular residual disease or MRD assay to detect tumor DNA.
The company said that it intends to deliver an accurate and easily accessible MRD array with the help of Janssen.
MRD testing is used in oncology to predict disease recurrence.
Currently, Illumina's stock is trading down 1.77 percent, to $128.92 on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Illumina Inc.mehr Nachrichten
Analysen zu Illumina Inc.mehr Analysen
Aktien in diesem Artikel
| Illumina Inc. | 115,02 | 4,45% |
|